ANK1

Across TCGA pan-cancer cohorts, ANK1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANK1 data layer compared with 24 for mass-spec protein and 16 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANK1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANK1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where ANK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.909	0.702	.002	30	view →
COAD	DFS	Median	III,IV	1.000	0.847	.047	12	view →
PDAC	OS	Median	III,IV	0.537	1.000	.008	7	view →
LSCC	DFS	Median	All	0.893	0.976	.024	3	view →
UCEC	OS	Quartile	All	0.881	1.000	.040	2	view →
LUAD	DFS	Quartile	All	1.000	0.613	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANK1–CCRCC (DFS)

Open the CCRCC breakdown →